Development Of A Subcutaneous Immunotherapy (SCIT) With A Modified Peanut Extract Formulation For The Treatment Of Peanut Allergy

Projekt: Uppdragsforskning

Projektinformation

Beskrivning

A First-in-human, Randomized, Double Blind, Placebo Controlled, Single-centre Study to Assess the Safety and Tolerability of HAL-MPE1 in Patients With Peanut Allergy
Kort titelHAL-MPE1 First-in-human
StatusSlutfört
Gällande start-/slutdatum2014/06/01 → 2015/06/30

Samarbetspartner

  • HAL Allergy Group
  • Odense University Hospital (huvudsaklig)